Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a blank-check company organized to pursue a business combination in the healthcare and life sciences sector, with a strategic emphasis on translational medicine and development-stage therapeutics. The SPAC completed its initial public offering in 2021 and has remained an active SEC reporting company, filing its most recent Form 10-Q on May 15, 2025, under accession number 0001410578-25-001344. The vehicle is sponsored by Translational Development Sponsor LLC, reflecting a management team with operational and investment backgrounds in biopharmaceutical development. Investors and analysts tracking TDAC's deal status, financial position, and SEC filings can access the full data profile on SpacDesk — sign up at spacdesk.com for complete coverage.